Westpac Banking Corp boosted its holdings in Celgene Co. (NASDAQ:CELG) by 15.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 60,184 shares of the biopharmaceutical company’s stock after acquiring an additional 7,970 shares during the quarter. Westpac Banking Corp’s holdings in Celgene were worth $5,386,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of CELG. Johnson Financial Group Inc. increased its position in shares of Celgene by 4.5% during the 2nd quarter. Johnson Financial Group Inc. now owns 13,100 shares of the biopharmaceutical company’s stock valued at $1,040,000 after purchasing an additional 567 shares during the period. Hills Bank & Trust Co. boosted its stake in shares of Celgene by 4.9% during the 3rd quarter. Hills Bank & Trust Co. now owns 14,255 shares of the biopharmaceutical company’s stock worth $1,276,000 after acquiring an additional 672 shares in the last quarter. Winslow Evans & Crocker Inc. boosted its stake in shares of Celgene by 7.0% during the 3rd quarter. Winslow Evans & Crocker Inc. now owns 10,428 shares of the biopharmaceutical company’s stock worth $936,000 after acquiring an additional 680 shares in the last quarter. BancorpSouth Bank boosted its stake in shares of Celgene by 11.8% during the 2nd quarter. BancorpSouth Bank now owns 6,591 shares of the biopharmaceutical company’s stock worth $523,000 after acquiring an additional 697 shares in the last quarter. Finally, Banco de Sabadell S.A boosted its stake in shares of Celgene by 6.4% during the 2nd quarter. Banco de Sabadell S.A now owns 11,700 shares of the biopharmaceutical company’s stock worth $913,000 after acquiring an additional 700 shares in the last quarter. Hedge funds and other institutional investors own 73.87% of the company’s stock.
Shares of CELG opened at $72.22 on Friday. Celgene Co. has a 12-month low of $66.62 and a 12-month high of $110.81. The company has a debt-to-equity ratio of 4.06, a quick ratio of 1.99 and a current ratio of 2.13. The stock has a market cap of $49.06 billion, a P/E ratio of 10.56, a PEG ratio of 0.43 and a beta of 1.53.
Several research firms have recently weighed in on CELG. UBS Group set a $94.00 price objective on Celgene and gave the stock a “buy” rating in a research note on Saturday, October 27th. BidaskClub lowered Celgene from a “buy” rating to a “hold” rating in a research note on Thursday, September 13th. Leerink Swann set a $112.00 price objective on Celgene and gave the stock a “hold” rating in a research note on Friday, October 26th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Celgene in a research note on Thursday, October 11th. Finally, Cantor Fitzgerald began coverage on Celgene in a research note on Monday, October 1st. They set an “overweight” rating and a $100.00 price objective for the company. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $116.99.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.com-unik.info/2018/12/01/westpac-banking-corp-has-5-39-million-position-in-celgene-co-celg.html.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Recommended Story: Can individual investors take part in an IPO?
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.